By Ludwig Burger (Reuters) -French drugmaker Sanofi (EPA:SASY) (NASDAQ:SNY) on Friday increased its guidance for full-year earnings, citing strong sales of anti-inflammatory...
Investing.com - Provention Bio (NASDAQ: PRVB) reported first quarter EPS of $-0.370, $0.09 better than the analyst estimate of $-0.459. Revenue for the quarter came in at $10.77M...
By Scott Kanowsky Investing.com -- Sanofi SA (EPA:SASY) agreed to purchase US-based pharmaceutical firm Provention Bio (NASDAQ:PRVB) in a deal worth approximately $2.9 billion,...
By Liz Moyer Investing.com -- Stocks are falling as the shutdown of SVB Financial Group (NASDAQ:SIVB) sends shockwaves through the banking sector. Here are the midday movers for...
By Ludwig Burger and Dina Kartit (Reuters) -France's Sanofi (NASDAQ:SNY) SA on Monday agreed to acquire Provention Bio Inc (O:PRVB) for $2.9 billion to bolster its work on a...
Provention Bio Inc. (NASDAQ:PRVB) reported Q2 EPS of ($0.46), $0.04 better than the analyst estimate of ($0.50). Revenue for the quarter came in at $746 thousand versus the...
Provention Bio Inc. (NASDAQ:PRVB) reported Q1 EPS of ($0.35), $0.11 better than the analyst estimate of ($0.46). Revenue for the quarter came in at $580 thousand versus the...
The convenience foods we consume make us suffer from diabetes. Diabetes is also common in children under the age of 10. Sugar is the disease of humanity. Everyone around me uses insulin. Medicines for diabetes are humanity's greatest hope. This company will do great things. drug production is great. It gives hope and expectation.
0
earnings? they're in clinical trials.
0
going to pop tomorrow
0
it seems likely
0
why is premarket down? doesn't make sense. I see this as likely being approved as long as the PK data with FDA gets sorted out.